Genmab — Juli 2020
-
from 2019 : Janssen DuoBody Collaboration
In July 2012, we entered into a collaboration with Janssen to create and develop bispecific antibodies using our DuoBody platform. Under this agreement, Janssen received an exclusive worldwide license to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations. We recorded an upfront payment of $3.5 million from Janssen and will potentially be entitled to milestone and -
and license payments of up to approximately $175.0 million, as well as royalties for each commercialized DuoBody product. Janssen may terminate this agreement in whole or with respect to any particular target binding pair upon providing 120 days' prior written notice to us in accordance with the terms of the agreement.
-
Under the terms of a December 2013 amendment, Janssen was entitled to work on up to 10 additional programs. In exchange, we recorded an initial payment of $2.0 million from Janssen and are potentially entitled to receive average milestone and license payments of approximately $191.0 million if Janssen successfully initiates, develops and commercializes all such additional programs. In addition, we will be entitled to royalties on net sales of any commercialized products.
-
As of March 31, 2019, Janssen has exercised 14 licenses under this collaboration and we have recorded $60.0 million in milestone payments to date. No further options remain for potential use by Janssen. Six product candidates are currently in clinical development by Janssen under this agreement.
-
Do we know if this amivantamab/lazertinib kombo is targetting first line lung cancer patients?
-
Indtil videre er det kun NSCLC med Exon 19 mutationen forsøgene går efter. Jeg mener, at det er 15-20% af hele NSCLC populationen - herunder first line. https://mc.vanderbilt.edu/ckm/gl/mutation_profiles/pdfopen.php?fnp=lung_cancer/content/EGFR/Lung_Cancer_and_EGFR_Exon_19_Deletions.pdf
-
Tak for svar til Solsen og Bulder
-
About 20 percent of NSCLC cases have somatic EGFR mutations. (15) Patients with the two most common mutations, EGFR L858R and EGFR exon deletion 19, are treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), which include erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib. https://www.mskcc.org/clinical-updates/systemic-therapy-locally-advanced-and-metastatic-non-small-cell-lung
-
Amgen dumps early-stage CD38xCD3 bispecific, returning rights to Xencor https://endpts.com/amgen-dumps-early-stage-cd38xcd3-bispecific-returning-rights-to-xencor-picked-up-in-2015-alliance/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind